# Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma

> **NCT03033576** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 94 (actual)

## Conditions studied

- Clinical Stage III Cutaneous Melanoma AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Melanoma of Unknown Primary
- Mucosal Melanoma
- Unresectable Cutaneous Melanoma
- Unresectable Melanoma

## Interventions

- **BIOLOGICAL:** Ipilimumab
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT03033576
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-23
- **Primary completion:** 2023-09-19
- **Final completion:** 2024-03-20
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2025-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03033576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03033576, "Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03033576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*